

Join us for a Prime Time Event, Presented by PeerVoice

Visit us at www.peervoice.com/LowerLipidsNOLA

The Power of Prevention: Lipid-Lowering Strategies for Cardiovascular Risk Reduction

Expert perspectives from:



MODERATOR

**Michael H. Davidson, MD,
FACC, FNLA**

The University of Chicago
Pritzker School of Medicine
Chicago, Illinois, USA



FACULTY

**Christie M. Ballantyne, MD,
FACC, FAHA, FNLA**

Baylor College of Medicine
Houston Methodist DeBakey Heart
and Vascular Center
Houston, Texas, USA



FACULTY

Christopher P. Cannon, MD

Brigham and Women's Hospital
Harvard Medical School
Boston, Massachusetts, USA

Eat, Drink, and Educate!

Sunday, March 17, 2019

6:00 PM – Registration and
Welcome Reception

6:30 PM – Symposium

New Orleans Downtown Marriott
Blaine Kern Ballroom

Directly across the street from the convention center

This event is not part of ACC.19, as planned by its Program Committee, and does not qualify for continuing medical education (CME), continuing nursing education (CNE) or continuing education (CE) credit.

PeerVoice

Join us for this live event designed to explore recent advances in the management of patients with high-risk cardiovascular disease.

Visit us at www.peervoice.com/LowerLipidsNOLA

The Power of Prevention: Lipid-Lowering Strategies for Cardiovascular Risk Reduction

AGENDA

- 6:00 PM ○ Registration and Welcome Reception
- 6:30 PM ○ Welcome and Introduction
- 6:35 PM ○ Rethinking Cardiovascular Risk Reduction: Spotlight on Lipid Management
- 6:45 PM ○ So Many Lipid Guidelines, So Little Time: What We Should Be Doing Now
- 7:00 PM ○ Game Changers in CVD Risk Reduction: Clinical Data That May Change Your Practice
- 7:10 PM ○ Pharmacoeconomics of Novel Lipid-Lowering Therapies: What You (and Your Patients) Need to Know
- 7:25 PM ○ Practical Issues in Providing Lipid-Lowering Therapies: Perfecting the Process
- 7:35 PM ○ Faculty Q&A and Wrap-Up

LEARNING OBJECTIVES

- Evaluate the latest guideline recommendations for assessment and management of dyslipidemia in high-risk patients
- Formulate a treatment plan to optimize cardiovascular risk reduction, based on guideline recommendations and available clinical data
- Assess the pharmacoeconomic impact of the latest guideline updates and clinical data for PCSK9 inhibitors

This activity is supported by an educational grant from Sanofi US and Regeneron Pharmaceuticals.

PeerVoice activities are designed to fill the unmet needs of the medical community by reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. The preparation of PeerVoice activities is supported by written agreements that clearly stipulate and enforce the editorial independence of PeerVoice and the faculty presenters.

Copyright © 2010-2019, PeerVoice

PeerVoice